Gufic Biosciences Limited (BOM:509079)

Market Cap	29.26B -14.7%
Revenue (ttm)	8.97B +10.8%
Net Income	500.38M -39.0%
EPS	4.99 -39.0%
Shares Out	100.28M
PE Ratio	58.51
Forward PE	n/a
Dividend	0.10 (0.03%)
Ex-Dividend Date	Sep 22, 2025

Volume	104,107
Average Volume	6,699
Open	288.95
Previous Close	281.45
Day's Range	287.40 - 304.35
52-Week Range	268.65 - 409.00
Beta	-0.14
RSI	50.90
Earnings Date	May 29, 2026

About Gufic Biosciences

Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, and South America. The company manufactures APIs and bulk drugs, such as antifungals, anaethetics, immuno suppressants, anginotensin receptor blocker, and intermediates for antifungals. It also manufactures lyophilized injections for antibiotic, antifungal, cardiac medications, infertility treatments, antiviral solutions, and proton pump inhibitors (P...

• Industry: Pharmaceutical Preparations
• Founded: 1970
• Employees: 1,484
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 509079

Financial Performance

In fiscal year 2025, Gufic Biosciences's revenue was 8.20 billion, an increase of 1.63% compared to the previous year's 8.07 billion. Earnings were 696.50 million, a decrease of -19.14%.